Lighting Science (LSCG) 10-Q 15 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	13-May-15
Document and Entity Information [Abstract]
Entity Registrant Name	LIGHTING SCIENCE GROUP CORP
Document Type	10-Q
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		212,004,390
Amendment Flag	FALSE
Entity Central Index Key	866970
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$549,383	$1,609,297
Restricted cash	3,000,000	3,000,000
Accounts receivable, net	10,145,554	10,417,985
Inventories	28,093,828	22,726,162
Prepaid expenses	1,800,595	2,936,837
Other current assets	1,794,591	1,610,544
Total current assets	45,383,951	42,300,825
Property and equipment, net	2,166,389	2,650,115
Intangible assets, net	2,644,862	2,572,479
Pegasus Commitment	339,200	720,000
Debt issuance costs, less current portion	2,958,120	3,230,446
Other long-term assets	115,195	118,467
Total assets	53,607,717	51,592,332
Current liabilities:
Lines of credit	11,324,585	6,368,793
Current portion of long-term debt	67,749	58,574
Accounts payable	10,301,294	19,364,552
Provision for losses on non-cancelable purchase commitments	717,714	540,227
Accrued expenses	8,993,538	9,924,316
Total current liabilities	31,404,880	36,256,462
Note payable	28,163,286	27,813,061
Long-term debt, less current portion	16,524	35,272
Liabilities under derivative contracts	13,421,201	5,636,944
Total other liabilities	41,601,011	33,485,277
Total liabilities	73,005,891	69,741,739
Redeemable Convertible Preferred Stock	491,956,776	468,906,776
Commitments and contingencies
Stockholders' deficit:
Preferred stock, $.001 par value, authorized 25,000,000 shares, 113,609 shares of Series H, 62,365 shares of Series I and 70,000 shares of Series J issued and outstanding as of March 31, 2015 and 113,609 shares of Series H, 62,365 shares of Series I and 58,475 shares of Series J issued and outstanding as of December 31, 2014	0	0
Common stock, $.001 par value, authorized 975,000,000 shares, 214,488,468 and 212,452,636 shares issued as of March 31, 2015 and December 31, 2014, respectively	214,489	212,453
Additional paid-in capital	309,430,336	320,175,440
Accumulated deficit	-813,929,663	-800,328,573
Accumulated other comprehensive loss	-3,312,612	-3,358,003
Treasury stock, 2,505,000 shares as of March 31, 2015 and December 31, 2014, at cost	-3,757,500	-3,757,500
Total stockholders’ deficit	-511,354,950	-487,056,183
Total liabilities and stockholders’ deficit	53,607,717	51,592,332
Series H Preferred Stock [Member]
Current liabilities:
Redeemable Convertible Preferred Stock	227,220,149	227,220,149
Series I Preferred Stock [Member]
Current liabilities:
Redeemable Convertible Preferred Stock	124,736,627	124,736,627
Series J Preferred Stock [Member]
Current liabilities:
Redeemable Convertible Preferred Stock	$140,000,000	$116,950,000

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Redeemable Convertible Preferred Stock, par value (in Dollars per share)	$0.00	$0.00
Redeemable Convertible Preferred Stock, authorized shares	25,000,000	25,000,000
Common stock, par value (in Dollars per share)	$0.00	$0.00
Common stock, authorized shares	975,000,000	975,000,000
Common stock, shares issued	214,488,468	212,452,636
Treasury stock, shares	2,505,000	2,505,000
Series H Preferred Stock [Member]
Redeemable Convertible Preferred Stock, par value (in Dollars per share)	$0.00	$0.00
Redeemable Convertible Preferred Stock, authorized shares	135,000	135,000
Redeemable Convertible Preferred Stock, shares issued	113,609	113,609
Redeemable Convertible Preferred Stock, shares outstanding	113,609	113,609
Series I Preferred Stock [Member]
Redeemable Convertible Preferred Stock, par value (in Dollars per share)	$0.00	$0.00
Redeemable Convertible Preferred Stock, authorized shares	90,000	90,000
Redeemable Convertible Preferred Stock, shares issued	62,365	62,365
Redeemable Convertible Preferred Stock, shares outstanding	62,365	62,365
Series J Preferred Stock [Member]
Redeemable Convertible Preferred Stock, par value (in Dollars per share)	$0.00	$0.00
Redeemable Convertible Preferred Stock, authorized shares	70,000	70,000
Redeemable Convertible Preferred Stock, shares issued	70,000	58,475
Redeemable Convertible Preferred Stock, shares outstanding	70,000	58,475

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenue	$19,371,545	$25,925,841
Cost of goods sold (exclusive of depreciation shown below)	16,441,297	23,462,953
Gross profit	2,930,248	2,462,888
Operating expense:
Selling, distribution and administrative (includes related party expenses of $0 and $609,000 for the three months ended March 31, 2015 and 2014, respectively)	5,095,581	8,966,338
Research and development	1,181,313	1,544,024
Restructuring expense	83,704	205,052
Depreciation and amortization	506,072	1,076,010
Total operating expenses	6,866,670	11,791,424
Loss from operations	-3,936,422	-9,328,536
Other income (expense):
Interest income		411
Interest expense	-1,462,360	-1,343,225
Related party interest expense	-138,300
Increase in fair value of liabilities under derivative contracts	-8,100,772	-29,479,538
Other income, net	36,764	56,925
Total other expense	-9,664,668	-30,765,427
Loss before income tax expense	-13,601,090	-40,093,963
Net loss	-13,601,090	-40,093,963
Foreign currency translation gain	45,391	172,604
Comprehensive loss	($13,555,699)	($39,921,359)
Parent [Member]
Other income (expense):
Basic and diluted net loss per weighted average common share (in Dollars per share)	($0.07)	($0.33)
Basic and diluted weighted average number of common shares outstanding (in Shares)	287,758,558	170,973,536
Noncontrolling Interest [Member]
Other income (expense):
Basic and diluted net loss per weighted average common share (in Dollars per share)	($0.07)	($0.35)
Basic and diluted weighted average number of common shares outstanding (in Shares)	97,668,138	36,854,212

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Related party expenses	$0	$609,000

Condensed_Consolidated_Stateme2

Condensed Consolidated Statement of Stockholders' Deficit (Unaudited) (USD $)	Common Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Series J Warrants [Member]	Series J Preferred Stock [Member]	Total
		Series J Warrants [Member]	Series J Preferred Stock [Member]
Balance at Dec. 31, 2014	$212,453			$320,175,440	($800,328,573)	($3,358,003)	($3,757,500)			($487,056,183)
Balance (in Shares) at Dec. 31, 2014	212,452,636
Issuance of restricted stock and options for directors' compensation	2,034			9,067						11,101
Issuance of restricted stock and options for directors' compensation (in Shares)	2,033,905
Stock based compensation expense				905,396						905,396
Stock issued under equity compensation plans	2			250						252
Stock issued under equity compensation plans (in Shares)	1,927
Series J Warrants issued		3,638,443						3,638,443
Deemed dividends on Series J Redeemable Convertible Preferred Stock			-15,298,260						-15,298,260
Net loss					-13,601,090					-13,601,090
Foreign currency translation adjustment						45,391				45,391
Balance at Mar. 31, 2015	$214,489			$309,430,336	($813,929,663)	($3,312,612)	($3,757,500)			($511,354,950)
Balance (in Shares) at Mar. 31, 2015	214,488,468

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	($13,601,090)	($40,093,963)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	506,072	1,076,010
Issuance of restricted stock and stock options for directors' compensation	11,101	73,348
Stock based compensation expense	905,396	916,657
Non-cash sales incentive	64,285	90,861
Allowance for doubtful accounts receivable	35,725	25,768
Write-down of inventory	94,595	689,637
Provision for losses on non-cancelable purchase commitments	176,857	-112,527
Increase (decrease) in fair value of derivative contracts	8,100,772	29,479,538
Amortization of debt issuance costs	333,847	188,011
Medley discount accretion	194,768	84,399
Interest accrued on Medley Term Loan	155,457	69,501
Loss on disposal of assets		42,690
Changes in operating assets and liabilities:
Accounts receivable	262,155	-9,459,143
Inventories	-5,466,179	-3,396,648
Prepaid expenses	1,136,362	-402,433
Other current and long-term assets	-130,079	-1,914,922
Accounts payable	-9,052,644	-2,005,522
Accrued expenses and other liabilities	-920,378	-146,805
Net cash used in operating activities	-17,192,978	-24,795,543
Cash flows from investing activities:
Purchases of property and equipment	-2,835	-153,420
Capitalized patents	-91,889	-222,175
Proceeds from sale of property and equipment		370,100
Net cash used in investing activities	-94,724	-5,495
Cash flows from financing activities:
Net proceeds (payments) from draws on lines of credit and other short-term borrowings	4,955,792	-30,198,924
Proceeds from long-term borrowings		29,775,000
Payment of short and long-term debt	-9,573	-1,316
Debt issuance costs	-112,217
Decrease in restricted cash related to line of credit		2,000,000
Proceeds from issuance of common stock under equity compensation plans	252	1,962
Fees incurred on issuance of preferred stock	-134,817	-217,880
Net cash provided by financing activities	16,224,437	18,833,842
Effect of exchange rate changes on cash	3,351	84,859
Net decrease in cash	-1,059,914	-5,882,337
Cash and cash equivalents balance at beginning of period	1,609,297	11,195,412
Cash and cash equivalents balance at end of period	549,383	5,313,075
Supplemental disclosures:
Interest paid during the period	1,380,181	1,059,079
Series J Preferred Stock [Member]
Cash flows from financing activities:
Proceeds from issuance of Series J Redeemable Convertible Preferred Securities	11,525,000	17,475,000
Series H, I and J Preferred Stock [Member]
Non-cash investing and financing activities:
Deemed dividends	-15,298,260	-30,198,619
Pegasus Guaranty Warrants [Member]
Non-cash investing and financing activities:
Deemed dividends		($570,574)

Note_1_Description_of_Business

Note 1 - Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Description of Business and Basis of Presentation
	Overview
	Lighting Science Group Corporation (the “Company”) was incorporated in Delaware in 1988 and designs, develops, manufactures and markets general illumination products that exclusively use light emitting diodes (“LEDs”) as their light source. The Company’s product portfolio includes LED-based retrofit lamps (replacement bulbs) that can be used in existing light fixtures and sockets as well as purpose built LED-based luminaires (light fixtures) for many common indoor and outdoor residential, commercial, industrial and public infrastructure lighting applications. The Company assembles and manufactures products primarily through its contract manufacturers in Asia.
	Basis of Financial Statement Presentation
	The accompanying unaudited condensed consolidated financial statements are presented pursuant to the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) in accordance with the disclosure requirements for the quarterly report on Form 10-Q and therefore do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America (“GAAP”) for complete financial statements. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) necessary to fairly state the results for the interim periods presented. The condensed consolidated balance sheet as of December 31, 2014 is derived from the Company’s audited financial statements. Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results of the Company that may be expected for the year ending December 31, 2015. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements as of and for the year ended December 31, 2014 and notes thereto included in the Company’s Annual Report on Form 10-K filed with the SEC on March 31, 2015.
	The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in the accompanying consolidated financial statements.

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 2. Summary of Significant Accounting Policies
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expense during the reporting periods. The Company’s actual results could differ from these estimates.
	Restricted Cash
	As of March 31, 2015 and December 31, 2014, as required by the Company’s five-year term loan (as amended from time to time, the “Medley Term Loan”) with Medley Capital Corporation (“Medley”), the Company maintained a minimum restricted cash balance of $3.0 million to collateralize the Medley Term Loan. Changes in the restricted cash balance are reflected as a financing activity in the consolidated statement of cash flows.
	Accounts Receivable
	The Company records accounts receivable at the invoiced amount when its products are shipped to customers or when specific milestone billing requirements are completed. The Company’s accounts receivable balance is recorded net of allowances for amounts not expected to be collected from customers. This allowance for doubtful accounts is the Company’s best estimate of probable credit losses in the Company’s existing accounts receivable. Estimates used in determining the allowance for doubtful accounts are based on historical collection experience, age of receivables and known collectability issues. The Company writes off accounts receivable when it becomes apparent, based on age or customer circumstances, that such amounts will not be collected. The Company reviews its allowance for doubtful accounts on a quarterly basis. Recovery of bad debt amounts previously written off is recorded as a reduction of bad debt expense in the period the payment is collected. Generally, the Company does not require collateral for its accounts receivable and does not regularly charge interest on past due amounts. As of March 31, 2015 and December 31, 2014, the Company’s accounts receivable were reflected net of an allowance for doubtful accounts of $448,000 and $408,000, respectively.
	As of March 31, 2015 and December 31, 2014, $7.2 million and $5.4 million of eligible accounts receivable were pledged as collateral for the three year asset based revolving credit facility (as amended from time to time, the “FCC ABL”) entered into on April 25, 2014 with FCC, LLC d/b/a First Capital (“First Capital”).
	Revenue Recognition
	The Company records revenue when its products are shipped and title passes to customers. When sales of products are subject to certain customer acceptance terms, revenue from such sales is recognized once those terms have been met. The Company also provides its customers with limited rights of return for non-conforming shipments or product warranty claims.
	In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014‑09”). ASU 2014-09 seeks to clarify the principles for recognizing revenue and to develop a common revenue standard for GAAP and International Financial Reporting Standards. ASU 2014‑09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. The Company is currently evaluating the impact of adopting ASU 2014‑09, but the standard is not expected to have a significant effect on its consolidated financial statements.
	Product Warranties
	The Company generally provides a five-year limited warranty covering defective materials and workmanship of its products. Such warranty may require the Company to repair, replace or reimburse the purchaser for the purchase price of the product. The estimated costs related to warranties are accrued at the time products are sold based on various factors, including the Company’s stated warranty policies and practices, the historical frequency of claims and the cost to repair or replace its products under warranty. The warranty provision is included in accrued expenses on the condensed consolidated balance sheet. Changes in the warranty provision for the three months ended March 31, 2015 were as follows:
	Warranty provision as of December 31, 2014		$	4,789,470
	Additions to provision			563,109
	Less warranty costs			(1,319,405	)
	Warranty provision as of March 31, 2015		$	4,033,174
	Fair Value Measurements
	The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:
		•	Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.
		•	Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.
		•	Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.
	Fair Value of Financial Instruments
	Cash and cash equivalents, accounts receivable, accounts payable, amounts due under lines of credit and other short term borrowings, accrued expenses and note payable are carried at amounts that approximate their fair value due to the short-term maturity of these instruments and/or variable, market driven interest rates.
	The liabilities under derivative contracts, which represent warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), were initially recorded at fair value and subsequently reflected at their fair value at the end of each reporting period. The fair value of the warrant issued to The Home Depot, Inc. (the “THD Warrant”) in January 2011, is determined using the Monte Carlo valuation method and will be adjusted at each reporting date until the underlying shares have been earned for each year. Such adjustments will be recorded as a reduction in the related revenue (sales incentive) from The Home Depot. Once a portion of the THD Warrant vests it is recorded at its fair value at the end of each subsequent reporting period.
	Reclassification
	Certain prior period amounts in the accompanying consolidated financial statements have been reclassified to conform to the current year presentation. These reclassifications had no effect on previously reported net loss or stockholders’ deficit.

Note_3_Liquidity_and_Capital_R

Note 3 - Liquidity and Capital Resources	3 Months Ended
	Mar. 31, 2015
Liquidity And Capital Resources [Abstract]
Liquidity And Capital Resources [Text Block]	Note 3. Liquidity and Capital Resources
	As shown in the condensed consolidated financial statements, the Company has experienced significant net losses as well as negative cash flows from operations since its inception, resulting in an accumulated deficit of $813.9 million and stockholders’ deficit of $511.4 million as of March 31, 2015. The Company’s cash expenditures primarily relate to procurement of inventory, payment of salaries, employee benefits and other operating costs. The Company’s primary sources of liquidity have historically been borrowings from First Capital under the FCC ABL, from Medley under the Medley Term Loan and other previous lenders, as well as sales of Common Stock and the Company’s preferred stock to, and short-term loans from, affiliates of Pegasus Capital Advisors, L.P. (“Pegasus Capital”), including Pegasus Partners IV, L.P. (“Pegasus IV”), LSGC Holdings LLC (“LSGC Holdings”), LSGC Holdings II LLC (“Holdings II”), LSGC Holdings III LLC (“Holdings III”) and PCA LSG Holdings, LLC (“PCA Holdings” and collectively with Pegasus Capital, Pegasus IV, LSGC Holdings, Holdings II, Holdings III and their affiliates, “Pegasus”). Pegasus is the Company’s controlling stockholder.
	On February 19, 2014, the Company entered into an agreement with Medley (as amended from time to time the “Medley Loan Agreement”) pursuant to which the Company obtained the five-year, $30.5 million Medley Term Loan.
	On April 25, 2014, the Company entered into the FCC ABL, a three-year revolving credit facility with First Capital. As of March 31, 2015, the Company had $11.3 million outstanding under the FCC ABL and additional borrowing capacity of $4.5 million. As of March 31, 2015, the Company had cash and cash equivalents of $549,000 and an additional $3.0 million in restricted cash subject to a cash collateral dominion agreement pursuant to the Medley Term Loan. The FCC ABL provides the Company with a maximum borrowing capacity of $22.5 million, which capacity is based on a formula of eligible accounts receivable and inventory. The Company is required to comply with certain specified EBITDA requirements, maintain a specified lamp sourcing percentage and comply with maximum capital expenditure limits.
	Commencing on September 25, 2015, RW LSG Holdings LLC (“Riverwood”) and Pegasus will have the right to cause the Company to redeem their shares of Series H Convertible Preferred Stock (“Series H Preferred Stock”) and Series I Convertible Preferred Stock (“Series I Preferred Stock”), respectively. If either Riverwood or Pegasus elects to cause the Company to redeem its shares of Series H Preferred Stock or Series I Preferred Stock, all other holders of the applicable series will have the right to redeem their shares of Preferred Stock. In addition, commencing 10 business days after September 25, 2015, each of Portman Limited (“Portman”) and affiliates of Zouk Holdings Limited, jointly, has a contractual right to require the Company to redeem its shares of Series H Preferred Stock. The Company is also required to redeem the outstanding shares of its Series J Convertible Preferred Stock (“Series J Preferred Stock” and collectively with Series H Preferred Stock and Series I Preferred Stock, the “Preferred Stock”) (a) subject to certain limited exceptions, immediately prior to the redemption of the Series H Preferred Stock, Series I Preferred Stock or any other security that ranks junior to the Series J Preferred Stock and (b) on November 14, 2019, at the election of the holders of Series J Preferred Stock (a “Special Redemption”). Each holder of the Company’s preferred stock would also have the right to require it to redeem such shares upon the uncured material breach of the Company’s obligations under its outstanding indebtedness or the uncured material breach of the terms of the certificates of designation governing its preferred stock. In total, the maximum payment obligation of the Company in the event of a redemption of all the Series H, I and J Preferred Stock is $492.0 million. Finally, the Company would be required to pay its outstanding obligations under the Medley Term Loan and the FCC ABL prior to any such redemption of shares of Preferred Stock. As of March 31, 2015, the aggregate borrowings outstanding under these loan facilities was $39.5 million.
	Any redemption of the Preferred Stock would be limited to funds legally available therefor under Delaware law. The certificates of designation governing the Company's preferred stock provide that if there is not a sufficient amount of cash or surplus available to pay for a redemption of Preferred Stock, then the redemption shall be paid out of the remaining assets of the Company. In addition, the Amended and Restated Certificate of Designation of Series J Preferred Stock provides that the Company is not permitted or required to redeem any shares of Series J Preferred Stock for so long as such redemption would result in an event of default under the Company’s credit facilities. If the Company does not have sufficient capital available to redeem the Series J Preferred Stock in connection with a Special Redemption of the Series J Preferred Stock, the Company will be required to issue a non-interest bearing note or notes (payable 180 days after issuance) in the principal amount of the liquidation amount of any shares of Series J Preferred Stock not redeemed by the Company in connection with such Special Redemption, subject to certain limitations imposed by Delaware law governing distributions to stockholders. As of March 31, 2015, based solely on a review of the Company’s balance sheet, the Company did not have legally available funds under Delaware law to satisfy a redemption of its Preferred Stock. In addition, based solely on the Company’s projected balance sheet as of September 25, 2015, the Company does not believe that it will have legally available funds on or before September 25, 2015 to satisfy any such redemption.
	On January 30, 2015, the Company issued an additional 11,525 units of its Series J securities (“Series J Securities”), at a purchase price of $1,000 per Series J Security for aggregate proceeds of $11.5 million. Each Series J Security consists of (i) one share of Series J Preferred Stock and (ii) a warrant to purchase 2,650 shares of the Company’s Common Stock, at an exercise price of $0.001 per share (the “Series J Warrants”). The Series J Securities were issued pursuant to a subscription agreement entered into between the Company and Holdings III.
	The Company continues to face challenges in its efforts to achieve positive cash flows from operations and profitability. The Company’s ability to meet its obligations in the ordinary course of business is dependent upon establishing profitable operations, which may be supplemented by any additional funds raised through public or private financing or increased borrowing capacity. The current business plan includes a focus on increasing revenue by updating and expanding our product offerings and capitalizing on the known product needs of our existing customers, improving gross margins by significantly leveraging contract manufacturers in Asia and reducing operating costs, primarily through the restructuring initiated in 2013. In future periods, if the Company does not adequately execute upon its business plan or its assumptions or forecasts do not prove to be accurate, the Company could exhaust its available capital resources, which could require the Company to seek to raise additional capital and/or further reduce its expenditures of cash. There can be no assurance that sources of liquidity will be available in an amount or on terms that are acceptable to the Company, if at all.

Note_4_Detail_of_Certain_Balan

Note 4 - Detail of Certain Balance Sheet Accounts	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block Supplement [Abstract]
Supplemental Balance Sheet Disclosures [Text Block]	Note 4. Detail of Certain Balance Sheet Accounts
	Inventories
	Inventories consisted of finished goods as of March 31, 2015 and December 31, 2014. As of March 31, 2015 and December 31, 2014, inventories were stated net of inventory write downs of $6.6 million and $7.9 million, respectively. The Company considered a number of factors in estimating the required inventory write downs, including (i) the focus of the business on the next generation of the Company’s products, which utilize lower cost technologies, (ii) the strategic focus on core products to meet the demands of key customers and (iii) the expected demand for the Company’s current generation of products, which is approaching the end of its lifecycle upon the introduction of the next generation of products.
	Property and Equipment, Net
	Property and equipment, net consisted of the following as of the dates indicated:
		31-Mar-15			31-Dec-14
	Leasehold improvements	$	158,421		$	158,421
	Office furniture and equipment		293,184			293,183
	Computer hardware and software		7,882,067			7,876,262
	Tooling, production and test equipment		4,559,918			4,559,942
	Trailers		45,996			45,996
	Construction-in-process		42,855			45,817
	Total property and equipment		12,982,441			12,979,621
	Accumulated depreciation		(10,816,052	)		(10,329,506	)
	Total property and equipment, net	$	2,166,389		$	2,650,115
	Depreciation related to property and equipment was $487,000 and $1.1 million for the three months ended March 31, 2015 and 2014, respectively.

Note_5_Intangible_Assets

Note 5 - Intangible Assets	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block [Abstract]
Intangible Assets Disclosure [Text Block]	Note 5. Intangible Assets
	Intangible assets that have finite lives are amortized over their useful lives. The Company’s intangible assets as of March 31, 2015 and December 31, 2014 are detailed below:
		Cost, Less		Accumulated			Net		Estimated
		Impairment		Amortization			Book Value		Remaining
		Charges							Useful Life
	March 31, 2015:
	Technology and intellectual property	$	2,888,469	$	(243,607	)	$	2,644,862	2.4 to 20.0 years
	December 31, 2014:
	Technology and intellectual property	$	2,796,580	$	(224,101	)	$	2,572,479	2.7 to 20.0 years
	Total intangible asset amortization expense was $20,000 and $14,000 for the three months ended March 31, 2015 and 2014, respectively.

Note_6_Debt_Issuance_Costs

Note 6 - Debt Issuance Costs	3 Months Ended
	Mar. 31, 2015
Debt Issuance Costs [Abstract]
Debt Issuance Costs [Text Block]	Note 6. Debt Issuance Costs
	The Company capitalizes its costs related to the issuance of long-term debt and amortizes these costs using the effective interest rate method over the life of the loan. Amortization of debt issuance costs and the accelerated write-off of debt issuance costs in connection with refinancing activities are recorded as a component of interest expense. As of March 31, 2015, the current portion of the debt issuance costs was $1.4 million and was included in other current assets. In connection with the FCC ABL and the Medley Term Loan, $6.0 million of debt issuance costs were capitalized, including $2.8 million related to the fair value of the guaranty of the Company’s obligations under the Medley Loan Agreement in favor of Medley (the “Pegasus Guaranty”) provided by Pegasus Capital Partners IV, L.P. and Pegasus Capital Partners V, L.P. (collectively, the “Pegasus Guarantors”). The Company amortized $334,000 and $188,000 of debt issuance costs for the three months ended March 31, 2015 and 2014, respectively.

Note_7_Lines_of_Credit_and_Not

Note 7 - Lines of Credit and Note Payable	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 7. Lines of Credit and Note Payable
		Balance Outstanding as of
	Facility	31-Mar-15		31-Dec-14
	First Capital, revolving line of credit	$	11,324,585	$	6,368,793
	Medley Term Loan		28,163,286		27,813,061
		$	39,487,871	$	34,181,854
	First Capital
	On April 25, 2014, the Company, entered into the FCC ABL, which provides the Company with a maximum borrowing capacity of $22.5 million, which capacity is based on a formula of eligible accounts receivable and inventory. As of March 31, 2015, the Company had $11.3 million outstanding under the FCC ABL and additional borrowing capacity of $4.5 million. As of March 31, 2015, eligible collateral included $7.2 million of accounts receivable and $10.0 million of inventory. Borrowings under the FCC ABL bear interest at a floating rate equal to one-month LIBOR plus 4.0% per annum. As of March 31, 2015, the interest rate on the FCC ABL was 4.17%.
	On January 30, 2015, the Company entered into an amendment to the FCC ABL, which provided additional notification and consent requirements as well as updates to certain disclosure schedules to the FCC ABL agreement. In connection with this amendment FCC also agreed to amend the calculation of EBITDA for purposes of determining compliance with the fixed charge coverage ratio covenant for each of the six-month period ending March 31, 2015, the nine month period ending June 30, 2015, the twelve-month period ending September 30, 2015 and the twelve-month period ending December 31, 2015.
	Medley Term Loan
	On February 19, 2014, the Company entered into the Medley Term Loan, which provided the Company with a $30.5 million term loan facility. The Medley Term Loan bears interest at a floating rate equal to three-month LIBOR plus 12% per annum, and as of March 31, 2015, the interest rate on the Medley Term Loan was 12.26%. Additionally, $3.0 million of the Medley Term Loan was funded directly into a deposit account to which Medley has exclusive access, to further secure the loan. The outstanding principal balance and all accrued and unpaid interest on the Medley Term Loan are due and payable on February 19, 2019. As of March 31, 2015 the balance of the Medley Term Loan was $28.2 million. The Company recognized $195,000 of interest expense for the accretion of the discounts to the balance of the Medley Term Loan related to the commitment fees and the Medley Warrants and $155,000 of accrued interest for the three months ended March 31, 2015 and $84,000 of interest expense for the accretion of the discounts to the balance of the Medley Term Loan related to the commitment fees and the Medley Warrants and $70,000 of accrued interest for the period from February 19, 2014 (date of issuance) to March 31, 2014.
	On January 30, 2015, the Company entered into an amendment to the Medley Term Loan, which provided additional notification and consent requirements, amends the minimum EBITDA covenant levels with respect to each of the six-month period ending March 31, 2015, the nine-month period ending June 30, 2015, the twelve-month period ending September 30, 2015 and the twelve-month period ending December 31, 2015, amends the definition of Fixed Charge Coverage Ratio and includes updates to certain disclosure schedules to the Medley Term Loan agreement.

Note_8_Fair_Value_Measurements

Note 8 - Fair Value Measurements	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	Note 8. Fair Value Measurements
	The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2015, according to the valuation techniques the Company used to determine their fair values:
		Fair Value Measurement as of March 31, 2015
		Quoted Price in Active Markets for Identical Assets			Significant Other Observable Inputs			Significant Unobservable Inputs
		Level 1			Level 2			Level 3
	Assets (Recurring):
	Pegasus Commitment	$	-		$	-		$	339,200
	Liabilities (Recurring):
	Riverwood Warrants	$	-		$	-		$	5,836,645
	September 2012 Warrants		-			-			339,200
	Pegasus Warrant		-			-			3,226,000
	THD Warrant		-			-			411,074
	Medley Warrants		-			-			1,749,254
	Pegasus Guaranty Warrants		-			-			1,859,028
		$	-		$	-		$	13,421,201
	The following table is a reconciliation of the beginning and ending balances for assets and liabilities that were accounted for at fair value on a recurring basis using Level 3 inputs, as defined above, for the three months ended March 31, 2015:
					Realized and unrealized			Purchases,			Transfers
					gains (losses)			sales,			in
		Balance			included			issuances and			or out of		Balance
		31-Dec-14			in net loss			settlements			Level 3		31-Mar-15
	Pegasus Commitment	$	720,000		$	(380,800	)	$	-		$	-	$	339,200
	Riverwood Warrants		(2,352,027	)		(3,484,618	)		-			-		(5,836,645	)
	September 2012 Warrants		(720,000	)		380,800			-			-		(339,200	)
	Pegasus Warrant		(1,300,000	)		(1,926,000	)		-			-		(3,226,000	)
	THD Warrant		(43,928	)		(367,146	)		-			-		(411,074	)
	Medley Warrants		(577,065	)		(1,172,189	)		-			-		(1,749,254	)
	Pegasus Guaranty Warrants		(643,924	)		(1,215,104	)		-			-		(1,859,028	)
	Total	$	(4,916,944	)	$	(8,165,057	)	$	-		$	-	$	(13,082,001	)
	The following table is a reconciliation of the beginning and ending balances for assets and liabilities that were accounted for at fair value on a recurring basis using Level 3 inputs, as defined above, for the three months ended March 31, 2014:
					Realized and unrealized			Purchases, sales,			Transfers in
		Balance			gains (losses) included			issuances and			or out of		Balance
		31-Dec-13			in net loss			settlements			Level 3		31-Mar-14
	Pegasus Commitment	$	1,407,335		$	432,665		$	-		$	-	$	1,840,000
	Riverwood Warrants		(5,002,664	)		(2,053,415	)		-			-		(7,056,079	)
	September 2012 Warrants		(1,407,335	)		(432,665	)		-			-		(1,840,000	)
	Pegasus Warrant		(2,765,047	)		(1,134,953	)		-			-		(3,900,000	)
	Series J Warrants		-			(26,134,232	)		(12,505,739	)		-		(38,639,971	)
	Medley Warrants		-			(74,954	)		(3,170,361	)		-		(3,245,315	)
	Pegasus Guaranty Warrants		-			(81,984	)		(3,336,574	)		-		(3,418,558	)
	Total	$	(7,767,711	)	$	(29,479,538	)	$	(19,012,674	)	$	-	$	(56,259,923	)

Note_9_Stockholders_Equity

Note 9 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 9. Stockholders’ Equity
	For the three months ended March 31, 2015 and 2014, the Company recorded expense of $11,000 and $73,000, respectively, related to restricted stock awards to the Company’s directors.
	On June 12, 2014, the Board approved the formation of a Scientific Advisory Board (the “SAB”) and issued restricted stock awards to each of the five members of the SAB as part of their compensation package. For the three months ended March 31, 2015, the Company recorded expense of $33,000 related to restricted stock awards to the Company’s SAB.
	Warrants for the Purchase of Common Stock
	As of March 31, 2015, the following warrants for the purchase of Common Stock were outstanding:
	Warrant Holder	Reason for Issuance	Number of Common Shares		Exercise Price				Expiration Date
	Investors in rights offering	Series D Warrants		1,072,617	$	2.95	to	$2.96	March 3, 2022 through April 19, 2022
	The Home Depot	Purchasing agreement		7,609,183	$		1.05		December 31, 2015 through 2018
	RW LSG Management Holdings LLC	Riverwood Warrants		12,664,760			Variable		25-May-22
	Certain other investors	Riverwood Warrants		5,427,751			Variable		25-May-22
	Cleantech Europe II (A) LP	September 2012 Warrants		3,406,041	$		0.72		25-Sep-22
	Cleantech Europe II (B) LP	September 2012 Warrants		593,959	$		0.72		25-Sep-22
	Portman Limited	September 2012 Warrants		4,000,000	$		0.72		25-Sep-22
	Aquillian Investments LLC	Private Placement Series H		830,508	$		1.18		25-Sep-17
	Pegasus	Pegasus Warrant		10,000,000			Variable		25-May-22
	Investors in Series J Follow-On Offering	Series J Warrants		185,500,000	$		0.001		January 3, 2019 through January 30, 2020
	Medley	Medley Warrants		10,000,000	$		0.95		19-Feb-24
	Pegasus	Pegasus Guaranty Warrants		10,000,000	$		0.5		19-Feb-24
				251,104,819

Note_10_Earnings_Loss_Per_Shar

Note 10 - Earnings (Loss) Per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note 10: Earnings (Loss) Per Share
	In 2012, the Company determined that two classes of Common Stock had been established for financial reporting purposes only, with Common Stock attributable to controlling stockholders representing shares beneficially owned and controlled by Pegasus and the Common Stock attributable to noncontrolling stockholders representing the minority interest stockholders. For the three months ended March 31, 2015 and 2014, the Company computed net loss per share of noncontrolling stockholders and controlling stockholders of Common Stock using the two-class method. Net loss from operations is initially allocated based on the underlying common shares held by controlling and noncontrolling stockholders. The allocation of the net losses attributable to the Common Stock attributable to controlling stockholders is then reduced by the amount of the deemed dividend related to the warrants issued to the Pegasus Guarantors, while the allocation of net losses attributable to the Common Stock attributable to noncontrolling stockholders is increased by the amount of the deemed dividend related to the warrants issued to the Pegasus Guarantors.
	The following table sets forth the computation of basic and diluted net loss per share of Common Stock:
		For the Three Months Ended March 31,
		2015						2014
		Controlling Stockholders			Noncontrolling Stockholders			Controlling Stockholders			Noncontrolling Stockholders
	Basic and diluted net income per share:
	Net loss attributable to common stock	$	(10,154,538	)	$	(3,446,552	)	$	(32,984,078	)	$	(7,109,885	)
	Deemed dividends related to the Series J Preferred Stock attributable to all shareholders		(11,421,641	)		(3,876,619	)		(24,843,481	)		(5,355,138	)
	Deemed dividends due to the issuance of Pegasus Guaranty Warrants as compensation for guaranty provided by controlling shareholders		-			-			570,574			(570,574	)
	Undistributed net loss	$	(21,576,179	)	$	(7,323,171	)	$	(57,256,985	)	$	(13,035,597	)
	Basic and diluted weighted average number of common shares outstanding		287,758,558			97,668,138			170,973,536			36,854,212
	Basic and diluted net loss per common share	$	(0.07	)	$	(0.07	)	$	(0.33	)	$	(0.35	)
	Basic earnings per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding for the applicable period. The Series J Warrants have an exercise price of $0.001 per share of Common Stock, and are included in the weighted average number of shares of Common Stock outstanding as there are no conditions that must be satisfied before such warrant may be exercised into the shares of Common Stock underlying such warrants. Diluted earnings per share is computed in the same manner as basic earnings per share except the number of shares is increased to assume exercise of potentially dilutive stock options, unvested restricted stock and contingently issuable shares using the treasury stock method and convertible preferred shares using the if-converted method, unless the effect of such increases would be anti-dilutive. The Company had 204.0 million and 109.4 million common stock equivalents for the three months ended March 31, 2015 and 2014, respectively, which were not included in the diluted net loss per common share as the common stock equivalents were anti-dilutive, as a result of being in a net loss position.

Note_11_Related_Party_Transact

Note 11 - Related Party Transactions	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 11: Related Party Transactions
	Pegasus Capital is an affiliate of Pegasus IV and LSGC Holdings, which are the Company’s largest stockholders and beneficially owned approximately 88.7% of the Common Stock as of March 31, 2015.
	On January 30, 2015, the Company issued an additional 11,525 units of Series J Securities, at a purchase price of $1,000 per Series J Security for aggregate proceeds of $11.5 million. The Series J Securities were issued pursuant to a subscription agreement between the Company and Holdings III, an affiliate of Pegasus Capital.

Note_12_Restructuring_Expenses

Note 12 - Restructuring Expenses	3 Months Ended
	Mar. 31, 2015
Restructuring and Related Activities [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	Note 12. Restructuring Expense
	The following table summarizes the Company’s restructuring expense and related charges for the following periods ended March 31:
			For the Three Months Ended March 31,
			2015			2014
	Broad based reduction of facilities and personnel (1)		$	83,704		$	114,276
	Organization Optimization Initiative (2)			-			90,776
	Total		$	83,704		$	205,052
		-1	These charges relate to a significant cost reduction plan initiated during the fourth quarter of 2013 that includes moving the majority of the Company’s manufacturing to its contract manufacturers in Asia, related workforce reductions in Satellite Beach, Florida and cost reductions in our foreign subsidiaries. The Company estimates it will incur $200,000 in additional expenses throughout this cost reduction plan, primarily related to additional headcount reductions. These additional costs are expected to be incurred in the first half of 2015.
		-2	In September 2011, the Company began implementing a restructuring plan designed to further increase efficiencies across the organization and lower the overall cost structure. This restructuring plan included a reduction in full time headcount in the United States, which was completed in October 2011. In 2012, the Company extended the restructuring plan to further increase efficiencies across the organization and lower its overall cost structure. The plan included a significant reduction in full time headcount in Mexico resulting from the Company’s continued shift of its manufacturing and production processes to the Company’s contract manufacturer in Mexico, the replacement of 10 members of management in the United States following the completion of the Series H and I Preferred Offering in May 2012 and the closing of the Company’s offices in the United Kingdom and Australia. For the three months ended March 31, 2014, these expenses relate to the final liquidation of the Australian entity.
	As of March 31, 2015, the accrued liability associated with the restructuring and other related charges consisted of the following:
			Workforce			Excess			Other
			Reduction			Facilities			Exit Costs			Total
	Accrued liability as of December 31, 2014		$	959,240		$	311,269		$	180,840		$	1,451,349
	Charges			83,704			-			-			83,704
	Payments			(422,377	)		(67,127	)		(6,053	)		(495,557	)
	Accrued liability as of March 31, 2015		$	620,567		$	244,142		$	174,787		$	1,039,496
	The remaining accrual of $1.0 million as of March 31, 2015 is expected to be paid during the year ending December 31, 2015.
	The restructuring and other related charges are included in the line item restructuring expense in the condensed consolidated statement of operations and comprehensive loss.

Note_13_Concentrations_of_Cred

Note 13 - Concentrations of Credit Risk	3 Months Ended
	Mar. 31, 2015
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	Note 13. Concentrations of Credit Risk
	For the three months ended March 31, 2015 and 2014, the Company had one customer whose revenue represented 80% and 78% of total revenue, respectively.
	As of March 31, 2015 and December 31, 2014, the Company had one customer whose accounts receivable balance represented 81% and 66% of accounts receivable, net of allowances, respectively.

Note_14_Commitments_and_Contin

Note 14 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 14. Commitments and Contingencies
	Legal Proceedings
	The Company is subject to the possibility of loss contingencies arising in its business. Such contingencies are accounted for in accordance with ASC Topic 450, “Contingencies.” In determining loss contingencies, the Company considers the possibility of a loss and the ability to reasonably estimate the amount of such loss or liability. An estimated loss is recorded when it is considered probable that a liability has been incurred and when the amount of loss can be reasonably estimated. In the ordinary course of business, the Company is routinely a defendant in or party to various pending and threatened legal claims and proceedings. The Company believes that any liability resulting from these various claims, except as noted below, will not have a material adverse effect on its results of operations or financial condition; however, it is possible that extraordinary or unexpected legal fees could adversely impact the Company’s financial results during a particular period. During its ordinary course of business, the Company enters into obligations to defend, indemnify and/or hold harmless various customers, officers, directors, employees, and other third parties. These contractual obligations could give rise to additional litigation costs and involvement in court proceedings.
	On June 22, 2012, Geveran Investments Limited (“Geveran”), one of the Company’s stockholders, filed a lawsuit against the Company and several others in the Circuit Court of the Seventeenth Judicial Circuit in and for Broward County, Florida. On October 30, 2012, the court entered an order transferring the lawsuit to the Ninth Judicial Circuit in and for Orange County, Florida. The action, styled Geveran Investments Limited v. Lighting Science Group Corp., et al., Case No. 12-17738 (07) (the “Geveran Case”), names the Company as a defendant, as well as Pegasus Capital and nine other entities affiliated with Pegasus Capital; Richard Weinberg, our former Director and former interim Chief Executive Officer and a former partner of Pegasus Capital; Gregory Kaiser, a former Chief Financial Officer; J.P. Morgan Securities, LLC (“J.P. Morgan”); and two employees of J.P. Morgan. Geveran seeks rescission of its $25.0 million investment in the Company, as well as recovery of interest, attorneys’ fees and court costs, jointly and severally against the Company, Pegasus Capital, Mr. Weinberg, Mr. Kaiser, J.P. Morgan and the two J.P. Morgan employees, for alleged violations of Florida securities laws. Geveran alternatively seeks unspecified money damages, as well as recovery of court costs, for alleged common law negligent misrepresentation against these same defendants. In August 2014, the court granted Geveran’s motion to amend their first amended complaint to assert a claim for punitive damages against the defendants.
	On August 28, 2014, the court issued an Order Granting Plaintiff’s Motion for Partial Summary Judgment under its First Cause of Action for Violation of the Florida Securities and Investor Protection Act (the “August 28 Order”). As of May 14, 2015, the August 28 Order had not been entered. Once the August 28 Order is entered, the Company intends to appeal it. Together with the other defendants, the Company will have 30 days to post a bond during which time enforcement of the judgment would be stayed. The Company plans to have a bond posted to secure the judgment, which should result in the automatic stay of enforcement through the appeal process.
	While the court granted partial summary judgment in favor Geveran and the outcome of any litigation is inherently difficult to predict, the Company currently believes that it has strong defenses against Geveran’s claims. The Company has retained counsel, denies liability in connection with this matter and intends to continue to vigorously defend itself against the claims asserted by Geveran. Nonetheless, the amount of possible loss, if any, cannot be reasonably estimated at this time. The outcome, if unfavorable, could have a material adverse effect on the Company’s financial position. The Company believes that, subject to the terms and conditions of the relevant policies (including retention and policy limits), directors and officers’ insurance coverage will be available to cover the substantial majority of its legal fees and costs in this matter. However, given the unspecified nature of Geveran’s maximum damage claims, insurance coverage may not be available for, or such coverage may not be sufficient to fully pay, a judgment or settlement in favor of Geveran. Based upon the terms of an indemnification agreement described below, the Company has also paid, and is likely to pay in the in the future, reasonable legal expenses incurred by J.P. Morgan and its affiliates in this lawsuit in connection with the engagement of J.P. Morgan as placement agent for the private placement with Geveran. Such payments are not covered by the Company’s insurance coverage. The engagement letter executed with J.P. Morgan provides that the Company will indemnify J.P. Morgan and its affiliates from liabilities relating to J.P. Morgan’s activities as placement agent, unless such activities are finally judicially determined to have resulted from J.P. Morgan’s bad faith, gross negligence or willful misconduct.
	The Company is also a defendant in action brought by GE Lighting Solutions LLC in Federal District Court for the Northern District of Ohio in or about January 2013. GE Lighting asserts a claim of patent infringement against the Company under U.S Patent No. 6,787,999, entitled LED-Based Modular Lamp, and U.S. Patent No. 6,799,864, entitled High Power LED Power Pack for Spot Module Illumination, and seeks monetary damages and an injunction. The Company believes that it has strong defenses against plaintiff’s claims.  The Company has retained counsel, denies liability in connection with this matter and intends to continue to vigorously defend itself against the claims asserted by GE Lighting. However, there is no assurance that the Company will be successful in defending against this action. The outcome, if unfavorable, could have a material adverse effect on the Company’s financial position. Even if the outcome is favorable, this litigation could result in substantial costs to the Company, could be a distraction to management and could harm the Company’s financial position.
	In addition, the Company may be a party to a variety of legal actions, such as employment and employment discrimination-related suits, employee benefit claims, breach of contract actions, tort claims, shareholder suits, including securities fraud, intellectual property related litigation, and a variety of legal actions relating to its business operations. In some cases, substantial punitive damages may be sought. The Company currently has insurance coverage for certain of these potential liabilities. Other potential liabilities may not be covered by insurance, insurers may dispute coverage or the amount of insurance may not be sufficient to cover the damages awarded. In addition, certain types of damages, such as punitive damages, may not be covered by insurance and insurance coverage for all or certain forms of liability may become unavailable or prohibitively expensive in the future.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expense during the reporting periods. The Company’s actual results could differ from these estimates.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash
	As of March 31, 2015 and December 31, 2014, as required by the Company’s five-year term loan (as amended from time to time, the “Medley Term Loan”) with Medley Capital Corporation (“Medley”), the Company maintained a minimum restricted cash balance of $3.0 million to collateralize the Medley Term Loan. Changes in the restricted cash balance are reflected as a financing activity in the consolidated statement of cash flows.
Trade and Other Accounts Receivable, Policy [Policy Text Block]	Accounts Receivable
	The Company records accounts receivable at the invoiced amount when its products are shipped to customers or when specific milestone billing requirements are completed. The Company’s accounts receivable balance is recorded net of allowances for amounts not expected to be collected from customers. This allowance for doubtful accounts is the Company’s best estimate of probable credit losses in the Company’s existing accounts receivable. Estimates used in determining the allowance for doubtful accounts are based on historical collection experience, age of receivables and known collectability issues. The Company writes off accounts receivable when it becomes apparent, based on age or customer circumstances, that such amounts will not be collected. The Company reviews its allowance for doubtful accounts on a quarterly basis. Recovery of bad debt amounts previously written off is recorded as a reduction of bad debt expense in the period the payment is collected. Generally, the Company does not require collateral for its accounts receivable and does not regularly charge interest on past due amounts. As of March 31, 2015 and December 31, 2014, the Company’s accounts receivable were reflected net of an allowance for doubtful accounts of $448,000 and $408,000, respectively.
	As of March 31, 2015 and December 31, 2014, $7.2 million and $5.4 million of eligible accounts receivable were pledged as collateral for the three year asset based revolving credit facility (as amended from time to time, the “FCC ABL”) entered into on April 25, 2014 with FCC, LLC d/b/a First Capital (“First Capital”).
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition
	The Company records revenue when its products are shipped and title passes to customers. When sales of products are subject to certain customer acceptance terms, revenue from such sales is recognized once those terms have been met. The Company also provides its customers with limited rights of return for non-conforming shipments or product warranty claims.
	In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASU 2014‑09”). ASU 2014-09 seeks to clarify the principles for recognizing revenue and to develop a common revenue standard for GAAP and International Financial Reporting Standards. ASU 2014‑09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. The Company is currently evaluating the impact of adopting ASU 2014‑09, but the standard is not expected to have a significant effect on its consolidated financial statements.
Standard Product Warranty, Policy [Policy Text Block]	Product Warranties
	The Company generally provides a five-year limited warranty covering defective materials and workmanship of its products. Such warranty may require the Company to repair, replace or reimburse the purchaser for the purchase price of the product. The estimated costs related to warranties are accrued at the time products are sold based on various factors, including the Company’s stated warranty policies and practices, the historical frequency of claims and the cost to repair or replace its products under warranty. The warranty provision is included in accrued expenses on the condensed consolidated balance sheet. Changes in the warranty provision for the three months ended March 31, 2015 were as follows:
	Warranty provision as of December 31, 2014		$	4,789,470
	Additions to provision			563,109
	Less warranty costs			(1,319,405	)
	Warranty provision as of March 31, 2015		$	4,033,174
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value Measurements
	The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:
		•	Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.
		•	Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.
		•	Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date.
	Fair Value of Financial Instruments
	Cash and cash equivalents, accounts receivable, accounts payable, amounts due under lines of credit and other short term borrowings, accrued expenses and note payable are carried at amounts that approximate their fair value due to the short-term maturity of these instruments and/or variable, market driven interest rates.
	The liabilities under derivative contracts, which represent warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), were initially recorded at fair value and subsequently reflected at their fair value at the end of each reporting period. The fair value of the warrant issued to The Home Depot, Inc. (the “THD Warrant”) in January 2011, is determined using the Monte Carlo valuation method and will be adjusted at each reporting date until the underlying shares have been earned for each year. Such adjustments will be recorded as a reduction in the related revenue (sales incentive) from The Home Depot. Once a portion of the THD Warrant vests it is recorded at its fair value at the end of each subsequent reporting period
Reclassification, Policy [Policy Text Block]	Reclassification
	Certain prior period amounts in the accompanying consolidated financial statements have been reclassified to conform to the current year presentation. These reclassifications had no effect on previously reported net loss or stockholders’ deficit.

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Schedule of Product Warranty Liability [Table Text Block]	Warranty provision as of December 31, 2014	$	4,789,470
	Additions to provision		563,109
	Less warranty costs		(1,319,405	)
	Warranty provision as of March 31, 2015	$	4,033,174

Note_4_Detail_of_Certain_Balan1

Note 4 - Detail of Certain Balance Sheet Accounts (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block Supplement [Abstract]
Property, Plant and Equipment [Table Text Block]		31-Mar-15			31-Dec-14
	Leasehold improvements	$	158,421		$	158,421
	Office furniture and equipment		293,184			293,183
	Computer hardware and software		7,882,067			7,876,262
	Tooling, production and test equipment		4,559,918			4,559,942
	Trailers		45,996			45,996
	Construction-in-process		42,855			45,817
	Total property and equipment		12,982,441			12,979,621
	Accumulated depreciation		(10,816,052	)		(10,329,506	)
	Total property and equipment, net	$	2,166,389		$	2,650,115

Note_5_Intangible_Assets_Table

Note 5 - Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]		Cost, Less		Accumulated			Net		Estimated
		Impairment		Amortization			Book Value		Remaining
		Charges							Useful Life
	March 31, 2015:
	Technology and intellectual property	$	2,888,469	$	(243,607	)	$	2,644,862	2.4 to 20.0 years
	December 31, 2014:
	Technology and intellectual property	$	2,796,580	$	(224,101	)	$	2,572,479	2.7 to 20.0 years

Note_7_Lines_of_Credit_and_Not1

Note 7 - Lines of Credit and Note Payable (Tables)	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]		Balance Outstanding as of
	Facility	31-Mar-15		31-Dec-14
	First Capital, revolving line of credit	$	11,324,585	$	6,368,793
	Medley Term Loan		28,163,286		27,813,061
		$	39,487,871	$	34,181,854

Note_8_Fair_Value_Measurements1

Note 8 - Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]		Fair Value Measurement as of March 31, 2015
		Quoted Price in Active Markets for Identical Assets			Significant Other Observable Inputs			Significant Unobservable Inputs
		Level 1			Level 2			Level 3
	Assets (Recurring):
	Pegasus Commitment	$	-		$	-		$	339,200
	Liabilities (Recurring):
	Riverwood Warrants	$	-		$	-		$	5,836,645
	September 2012 Warrants		-			-			339,200
	Pegasus Warrant		-			-			3,226,000
	THD Warrant		-			-			411,074
	Medley Warrants		-			-			1,749,254
	Pegasus Guaranty Warrants		-			-			1,859,028
		$	-		$	-		$	13,421,201
Fair Value, Assets Measured on Recurring Basis [Table Text Block]					Realized and unrealized			Purchases,			Transfers
					gains (losses)			sales,			in
		Balance			included			issuances and			or out of		Balance
		31-Dec-14			in net loss			settlements			Level 3		31-Mar-15
	Pegasus Commitment	$	720,000		$	(380,800	)	$	-		$	-	$	339,200
	Riverwood Warrants		(2,352,027	)		(3,484,618	)		-			-		(5,836,645	)
	September 2012 Warrants		(720,000	)		380,800			-			-		(339,200	)
	Pegasus Warrant		(1,300,000	)		(1,926,000	)		-			-		(3,226,000	)
	THD Warrant		(43,928	)		(367,146	)		-			-		(411,074	)
	Medley Warrants		(577,065	)		(1,172,189	)		-			-		(1,749,254	)
	Pegasus Guaranty Warrants		(643,924	)		(1,215,104	)		-			-		(1,859,028	)
	Total	$	(4,916,944	)	$	(8,165,057	)	$	-		$	-	$	(13,082,001	)
					Realized and unrealized			Purchases, sales,			Transfers in
		Balance			gains (losses) included			issuances and			or out of		Balance
		31-Dec-13			in net loss			settlements			Level 3		31-Mar-14
	Pegasus Commitment	$	1,407,335		$	432,665		$	-		$	-	$	1,840,000
	Riverwood Warrants		(5,002,664	)		(2,053,415	)		-			-		(7,056,079	)
	September 2012 Warrants		(1,407,335	)		(432,665	)		-			-		(1,840,000	)
	Pegasus Warrant		(2,765,047	)		(1,134,953	)		-			-		(3,900,000	)
	Series J Warrants		-			(26,134,232	)		(12,505,739	)		-		(38,639,971	)
	Medley Warrants		-			(74,954	)		(3,170,361	)		-		(3,245,315	)
	Pegasus Guaranty Warrants		-			(81,984	)		(3,336,574	)		-		(3,418,558	)
	Total	$	(7,767,711	)	$	(29,479,538	)	$	(19,012,674	)	$	-	$	(56,259,923	)

Note_9_Stockholders_Equity_Tab

Note 9 - Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrant Holder	Reason for Issuance	Number of Common Shares		Exercise Price				Expiration Date
	Investors in rights offering	Series D Warrants		1,072,617	$	2.95	to	$2.96	March 3, 2022 through April 19, 2022
	The Home Depot	Purchasing agreement		7,609,183	$		1.05		December 31, 2015 through 2018
	RW LSG Management Holdings LLC	Riverwood Warrants		12,664,760			Variable		25-May-22
	Certain other investors	Riverwood Warrants		5,427,751			Variable		25-May-22
	Cleantech Europe II (A) LP	September 2012 Warrants		3,406,041	$		0.72		25-Sep-22
	Cleantech Europe II (B) LP	September 2012 Warrants		593,959	$		0.72		25-Sep-22
	Portman Limited	September 2012 Warrants		4,000,000	$		0.72		25-Sep-22
	Aquillian Investments LLC	Private Placement Series H		830,508	$		1.18		25-Sep-17
	Pegasus	Pegasus Warrant		10,000,000			Variable		25-May-22
	Investors in Series J Follow-On Offering	Series J Warrants		185,500,000	$		0.001		January 3, 2019 through January 30, 2020
	Medley	Medley Warrants		10,000,000	$		0.95		19-Feb-24
	Pegasus	Pegasus Guaranty Warrants		10,000,000	$		0.5		19-Feb-24
				251,104,819

Note_10_Earnings_Loss_Per_Shar1

Note 10 - Earnings (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]		For the Three Months Ended March 31,
		2015						2014
		Controlling Stockholders			Noncontrolling Stockholders			Controlling Stockholders			Noncontrolling Stockholders
	Basic and diluted net income per share:
	Net loss attributable to common stock	$	(10,154,538	)	$	(3,446,552	)	$	(32,984,078	)	$	(7,109,885	)
	Deemed dividends related to the Series J Preferred Stock attributable to all shareholders		(11,421,641	)		(3,876,619	)		(24,843,481	)		(5,355,138	)
	Deemed dividends due to the issuance of Pegasus Guaranty Warrants as compensation for guaranty provided by controlling shareholders		-			-			570,574			(570,574	)
	Undistributed net loss	$	(21,576,179	)	$	(7,323,171	)	$	(57,256,985	)	$	(13,035,597	)
	Basic and diluted weighted average number of common shares outstanding		287,758,558			97,668,138			170,973,536			36,854,212
	Basic and diluted net loss per common share	$	(0.07	)	$	(0.07	)	$	(0.33	)	$	(0.35	)

Note_12_Restructuring_Expenses1

Note 12 - Restructuring Expenses (Tables)	3 Months Ended
	Mar. 31, 2015
Note 12 - Restructuring Expenses (Tables) [Line Items]
Restructuring and Related Costs [Table Text Block]		For the Three Months Ended March 31,
		2015			2014
	Broad based reduction of facilities and personnel (1)	$	83,704		$	114,276
	Organization Optimization Initiative (2)		-			90,776
	Total	$	83,704		$	205,052
Accrued Liabilities and Other Charges [Member]
Note 12 - Restructuring Expenses (Tables) [Line Items]
Restructuring and Related Costs [Table Text Block]		Workforce			Excess			Other
		Reduction			Facilities			Exit Costs			Total
	Accrued liability as of December 31, 2014	$	959,240		$	311,269		$	180,840		$	1,451,349
	Charges		83,704			-			-			83,704
	Payments		(422,377	)		(67,127	)		(6,053	)		(495,557	)
	Accrued liability as of March 31, 2015	$	620,567		$	244,142		$	174,787		$	1,039,496

Note_2_Summary_of_Significant_2

Note 2 - Summary of Significant Accounting Policies (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Restricted Cash and Cash Equivalents, Current	$3,000,000
Allowance for Doubtful Accounts Receivable	448,000	408,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)	$0.00	$0.00
Medley Term Loan [Member] | Minimum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Restricted Cash and Cash Equivalents, Current	3,000,000
First Capital [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Debt Instrument, Collateral Amount	$7,200,000	$5,400,000

Note_2_Summary_of_Significant_3

Note 2 - Summary of Significant Accounting Policies (Details) - Summary of Warranty Provision (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Summary of Warranty Provision [Abstract]
Warranty provision	$4,033,174	$4,789,470
Additions to provision	563,109
Less warranty costs	($1,319,405)

Note_3_Liquidity_and_Capital_R1

Note 3 - Liquidity and Capital Resources (Details) (USD $)	0 Months Ended	3 Months Ended
	Jan. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
Note 3 - Liquidity and Capital Resources (Details) [Line Items]
Retained Earnings (Accumulated Deficit)		($813,929,663)	($800,328,573)
Stockholders' Equity Attributable to Parent		-511,354,950	-487,056,183
Cash and Cash Equivalents, at Carrying Value		549,383	1,609,297	5,313,075	11,195,412
Restricted Cash and Cash Equivalents, Current		3,000,000
Preferred Stock, Redemption Amount		492,000,000
Debt, Long-term and Short-term, Combined Amount		39,500,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)		251,104,819
Series J Preferred Stock [Member] | Series J Redeemable Convertible Preferred Stock [Member] | Holdings III [Member]
Note 3 - Liquidity and Capital Resources (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)	11,525
Proceeds from Issuance of Redeemable Preferred Stock	11,500,000
Series J Preferred Stock [Member]
Note 3 - Liquidity and Capital Resources (Details) [Line Items]
Share Price (in Dollars per share)	$1,000
Series J Warrants [Member]
Note 3 - Liquidity and Capital Resources (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)	2,650
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$0.00
Medley Term Loan [Member]
Note 3 - Liquidity and Capital Resources (Details) [Line Items]
Debt Instrument, Term		5 years
Line of Credit Facility, Maximum Borrowing Capacity		30,500,000
First Capital [Member]
Note 3 - Liquidity and Capital Resources (Details) [Line Items]
Debt Instrument, Term		3 years
Line of Credit Facility, Maximum Borrowing Capacity		22,500,000
Long-term Line of Credit		11,300,000
Line of Credit Facility, Remaining Borrowing Capacity		$4,500,000

Note_4_Detail_of_Certain_Balan2

Note 4 - Detail of Certain Balance Sheet Accounts (Details) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Inventory Valuation Reserves	$6,600,000
Inventory Write-down	94,595	689,637	7,900,000
Depreciation	$487,000	$1,100,000

Note_4_Detail_of_Certain_Balan3

Note 4 - Detail of Certain Balance Sheet Accounts (Details) - Property and Equipment (USD $)	Mar. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment	$12,982,441	$12,979,621
Accumulated depreciation	-10,816,052	-10,329,506
Total property and equipment, net	2,166,389	2,650,115
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	158,421	158,421
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	293,184	293,183
Computer Hardware and Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	7,882,067	7,876,262
Tooling, Production and Test Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	4,559,918	4,559,942
Trailers [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	45,996	45,996
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$42,855	$45,817

Note_5_Intangible_Assets_Detai

Note 5 - Intangible Assets (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Disclosure Text Block [Abstract]
Amortization of Intangible Assets	$20,000	$14,000

Note_5_Intangible_Assets_Detai1

Note 5 - Intangible Assets (Details) - Summary of Intangible Assets (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Net Book Value	2,644,862	2,572,479
Minimum [Member] | Technology and Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Remaining Useful Life	2 years 146 days	2 years 255 days
Maximum [Member] | Technology and Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Remaining Useful Life	20 years	20 years
Technology and Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Cost, Less Impairment Charges	2,888,469	2,796,580
Accumulated Amortization	-243,607	-224,101
Net Book Value	2,644,862	2,572,479

Note_6_Debt_Issuance_Costs_Det

Note 6 - Debt Issuance Costs (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Note 6 - Debt Issuance Costs (Details) [Line Items]
Amortization of Financing Costs	$333,847	$188,011
Other Current Assets [Member]
Note 6 - Debt Issuance Costs (Details) [Line Items]
Deferred Finance Costs, Current, Net	1,400,000
First Capital and Medley [Member]
Note 6 - Debt Issuance Costs (Details) [Line Items]
Debt Issuance Cost	6,000,000
Pegasus Guaranty [Member]
Note 6 - Debt Issuance Costs (Details) [Line Items]
Debt Issuance Cost		$2,800,000

Note_7_Lines_of_Credit_and_Not2

Note 7 - Lines of Credit and Note Payable (Details) (USD $)	3 Months Ended		12 Months Ended	1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Feb. 19, 2014
Note 7 - Lines of Credit and Note Payable (Details) [Line Items]
Line of Credit, Current	$11,324,585		$6,368,793
Restricted Cash and Cash Equivalents, Current	3,000,000
Notes Payable, Noncurrent	28,163,286		27,813,061
Accretion of Discount	194,768	84,399
Debt Instrument, Increase, Accrued Interest	-155,457	-69,501
Commitment Fees [Member] | Medley Warrants [Member] | Medley Capital Corporation [Member] | Medley Term Loan [Member]
Note 7 - Lines of Credit and Note Payable (Details) [Line Items]
Accretion of Discount	195,000		84,000
First Capital [Member] | London Interbank Offered Rate (LIBOR) [Member]
Note 7 - Lines of Credit and Note Payable (Details) [Line Items]
Debt Instrument, Basis Spread on Variable Rate	4.00%
First Capital [Member] | Accounts Receivable [Member]
Note 7 - Lines of Credit and Note Payable (Details) [Line Items]
Debt Instrument, Collateral Amount	7,200,000
First Capital [Member]
Note 7 - Lines of Credit and Note Payable (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	22,500,000
Line of Credit, Current	11,300,000
Line of Credit Facility, Remaining Borrowing Capacity	4,500,000
Debt Instrument, Collateral Amount	7,200,000		5,400,000
Line of Credit Facility, Eligible Collateral Inventory	10,000,000
Debt Instrument, Interest Rate, Effective Percentage	4.17%
Medley Capital Corporation [Member] | London Interbank Offered Rate (LIBOR) [Member] | Medley Term Loan [Member]
Note 7 - Lines of Credit and Note Payable (Details) [Line Items]
Debt Instrument, Basis Spread on Variable Rate				12.00%
Medley Capital Corporation [Member] | Medley Term Loan [Member]
Note 7 - Lines of Credit and Note Payable (Details) [Line Items]
Notes Payable				30,500,000
Accrued Interest Rate of Loan				12.26%
Restricted Cash and Cash Equivalents, Current	3,000,000
Notes Payable, Noncurrent	28,200,000
Debt Instrument, Increase, Accrued Interest	155,000		-70,000
Medley Term Loan [Member]
Note 7 - Lines of Credit and Note Payable (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	30,500,000
Notes Payable, Noncurrent	$28,163,286		$27,813,061

Note_7_Lines_of_Credit_and_Not3

Note 7 - Lines of Credit and Note Payable (Details) - Lines of Credit and Note Payable (USD $)	Mar. 31, 2015	Dec. 31, 2014
Note 7 - Lines of Credit and Note Payable (Details) - Lines of Credit and Note Payable [Line Items]
First Capital, revolving line of credit	$11,324,585	$6,368,793
Medley Term Loan	28,163,286	27,813,061
	39,487,871	34,181,854
Medley Term Loan [Member]
Note 7 - Lines of Credit and Note Payable (Details) - Lines of Credit and Note Payable [Line Items]
Medley Term Loan	28,163,286	27,813,061
First Capital [Member]
Note 7 - Lines of Credit and Note Payable (Details) - Lines of Credit and Note Payable [Line Items]
First Capital, revolving line of credit	$11,324,585	$6,368,793

Note_8_Fair_Value_Measurements2

Note 8 - Fair Value Measurements (Details) - Financial Assets and Liabilities Accounted For at Fair Value on a Recurring Basis (Fair Value, Measurements, Recurring [Member], Fair Value, Inputs, Level 3 [Member], USD $)	Mar. 31, 2015
Liabilities (Recurring):
Liabilities, Fair Value Disclosure, Recurring	$13,421,201
Pegasus Commitment [Member]
Assets (Recurring):
Pegasus Commitment	339,200
Riverwood Warrants [Member]
Liabilities (Recurring):
Liabilities, Fair Value Disclosure, Recurring	5,836,645
September 2012 Warrants [Member]
Liabilities (Recurring):
Liabilities, Fair Value Disclosure, Recurring	339,200
Pegasus Warrant [Member]
Liabilities (Recurring):
Liabilities, Fair Value Disclosure, Recurring	3,226,000
THD Warrant [Member]
Liabilities (Recurring):
Liabilities, Fair Value Disclosure, Recurring	411,074
Medley Warrants [Member]
Liabilities (Recurring):
Liabilities, Fair Value Disclosure, Recurring	1,749,254
Pegasus Guaranty Warrants [Member]
Liabilities (Recurring):
Liabilities, Fair Value Disclosure, Recurring	$1,859,028

Note_8_Fair_Value_Measurements3

Note 8 - Fair Value Measurements (Details) - Reconciliation of Beginning and Ending Balances for Assets and Liabilities Accounted For at Fair Value on a Recurring Basis (Fair Value, Inputs, Level 3 [Member], USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Note 8 - Fair Value Measurements (Details) - Reconciliation of Beginning and Ending Balances for Assets and Liabilities Accounted For at Fair Value on a Recurring Basis [Line Items]
Beginning balance	($4,916,944)	($7,767,711)
Realized and unrealized gains (losses) included in net loss	-8,165,057	-29,479,538
Purchases, sales, issuances and settlements		-19,012,674
Ending balance	-13,082,001	-56,259,923
Pegasus Commitment [Member]
Note 8 - Fair Value Measurements (Details) - Reconciliation of Beginning and Ending Balances for Assets and Liabilities Accounted For at Fair Value on a Recurring Basis [Line Items]
Beginning balance	720,000	1,407,335
Realized and unrealized gains (losses) included in net loss	-380,800	432,665
Ending balance	339,200	1,840,000
Riverwood Warrants [Member]
Note 8 - Fair Value Measurements (Details) - Reconciliation of Beginning and Ending Balances for Assets and Liabilities Accounted For at Fair Value on a Recurring Basis [Line Items]
Beginning balance	-2,352,027	-5,002,664
Realized and unrealized gains (losses) included in net loss	-3,484,618	-2,053,415
Ending balance	-5,836,645	-7,056,079
September 2012 Warrants [Member]
Note 8 - Fair Value Measurements (Details) - Reconciliation of Beginning and Ending Balances for Assets and Liabilities Accounted For at Fair Value on a Recurring Basis [Line Items]
Beginning balance	-720,000	-1,407,335
Realized and unrealized gains (losses) included in net loss	380,800	-432,665
Ending balance	-339,200	-1,840,000
Pegasus Warrant [Member]
Note 8 - Fair Value Measurements (Details) - Reconciliation of Beginning and Ending Balances for Assets and Liabilities Accounted For at Fair Value on a Recurring Basis [Line Items]
Beginning balance	-1,300,000	-2,765,047
Realized and unrealized gains (losses) included in net loss	-1,926,000	-1,134,953
Ending balance	-3,226,000	-3,900,000
THD Warrant [Member]
Note 8 - Fair Value Measurements (Details) - Reconciliation of Beginning and Ending Balances for Assets and Liabilities Accounted For at Fair Value on a Recurring Basis [Line Items]
Beginning balance	-43,928
Realized and unrealized gains (losses) included in net loss	-367,146
Ending balance	-411,074
Medley Warrants [Member]
Note 8 - Fair Value Measurements (Details) - Reconciliation of Beginning and Ending Balances for Assets and Liabilities Accounted For at Fair Value on a Recurring Basis [Line Items]
Beginning balance	-577,065
Realized and unrealized gains (losses) included in net loss	-1,172,189	-74,954
Purchases, sales, issuances and settlements		-3,170,361
Ending balance	-1,749,254	-3,245,315
Pegasus Guaranty Warrants [Member]
Note 8 - Fair Value Measurements (Details) - Reconciliation of Beginning and Ending Balances for Assets and Liabilities Accounted For at Fair Value on a Recurring Basis [Line Items]
Beginning balance	-643,924
Realized and unrealized gains (losses) included in net loss	-1,215,104	-81,984
Purchases, sales, issuances and settlements		-3,336,574
Ending balance	-1,859,028	-3,418,558
Series J Warrants [Member]
Note 8 - Fair Value Measurements (Details) - Reconciliation of Beginning and Ending Balances for Assets and Liabilities Accounted For at Fair Value on a Recurring Basis [Line Items]
Realized and unrealized gains (losses) included in net loss		-26,134,232
Purchases, sales, issuances and settlements		-12,505,739
Ending balance		($38,639,971)

Note_9_Stockholders_Equity_Det

Note 9 - Stockholders' Equity (Details) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jun. 12, 2014
Note 9 - Stockholders' Equity (Details) [Line Items]
Allocated Share-based Compensation Expense	$11,101	$73,348
Restricted Stock [Member] | Director [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Allocated Share-based Compensation Expense	11,000	73,000
Restricted Stock [Member] | Scientific Advisory Board [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Recipients			5
Scientific Advisory Board [Member]
Note 9 - Stockholders' Equity (Details) [Line Items]
Restricted Stock or Unit Expense	$33,000

Note_9_Stockholders_Equity_Det1

Note 9 - Stockholders' Equity (Details) - Warrants Outstanding for Purchase of Common Stock (USD $)	Mar. 31, 2015	Mar. 31, 2014
Class of Warrant or Right [Line Items]
Number of Common Shares	251,104,819
Series D Warrants [Member] | Investors in Rights Offering [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	2.95
Series D Warrants [Member] | Investors in Rights Offering [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)	2.96
Series D Warrants [Member] | Investors in Rights Offering [Member]
Class of Warrant or Right [Line Items]
Number of Common Shares	1,072,617
Purchasing Agreement [Member] | The Home Depot [Member]
Class of Warrant or Right [Line Items]
Number of Common Shares	7,609,183
Exercise Price (in Dollars per share)	1.05
Riverwood Warrants [Member] | RW LSG Management Holdings LLC [Member]
Class of Warrant or Right [Line Items]
Number of Common Shares	12,664,760
Riverwood Warrants [Member] | Certain Other Investors [Member]
Class of Warrant or Right [Line Items]
Number of Common Shares	5,427,751
September 2012 Warrants [Member] | Cleantech A [Member]
Class of Warrant or Right [Line Items]
Number of Common Shares	3,406,041
Exercise Price (in Dollars per share)	0.72
September 2012 Warrants [Member] | Portman [Member]
Class of Warrant or Right [Line Items]
Number of Common Shares	4,000,000
Exercise Price (in Dollars per share)	0.72
September 2012 Warrants [Member] | Cleantech B [Member]
Class of Warrant or Right [Line Items]
Number of Common Shares	593,959
Exercise Price (in Dollars per share)	0.72
Private Placement Series H [Member] | Acquillian Investments LLC [Member]
Class of Warrant or Right [Line Items]
Number of Common Shares	830,508
Exercise Price (in Dollars per share)	1.18
Pegasus Warrant [Member] | Pegasus Capital [Member]
Class of Warrant or Right [Line Items]
Number of Common Shares	10,000,000
Series J Warrants [Member] | Investors in Series J Follow-on Offering [Member]
Class of Warrant or Right [Line Items]
Number of Common Shares	185,500,000
Exercise Price (in Dollars per share)	0.001
Series J Warrants [Member]
Class of Warrant or Right [Line Items]
Exercise Price (in Dollars per share)		$0.00
Medley Warrants [Member] | Medley Capital Corporation [Member]
Class of Warrant or Right [Line Items]
Number of Common Shares	10,000,000
Exercise Price (in Dollars per share)	0.95
Pegasus Guaranty Warrants [Member] | Pegasus Capital [Member]
Class of Warrant or Right [Line Items]
Number of Common Shares	10,000,000
Exercise Price (in Dollars per share)	0.5

Note_10_Earnings_Loss_Per_Shar2

Note 10 - Earnings (Loss) Per Share (Details) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Note 10 - Earnings (Loss) Per Share (Details) [Line Items]
Method Used To Compute Net Loss Per Share Of Noncontrolling Shareholders And Controlling Shareholders Common Stock	two-class method	two-class method
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	204	109.4
Series J Warrants [Member]
Note 10 - Earnings (Loss) Per Share (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		0.001

Note_10_Earnings_Loss_Per_Shar3

Note 10 - Earnings (Loss) Per Share (Details) - Computation of Basic and Diluted Net Loss Per Share of Common Stock (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Basic and diluted net income per share:
Net loss attributable to common stock	($13,601,090)	($40,093,963)
Pegasus Guaranty Warrants [Member] | Controlling Shareholders [Member]
Basic and diluted net income per share:
Deemed dividends due to the issuance of Pegasus Guaranty Warrants as compensation for guaranty provided by controlling shareholders		570,574
Pegasus Guaranty Warrants [Member] | Noncontrolling Shareholders [Member]
Basic and diluted net income per share:
Deemed dividends due to the issuance of Pegasus Guaranty Warrants as compensation for guaranty provided by controlling shareholders		-570,574
Controlling Shareholders [Member] | Series J Preferred Stock [Member]
Basic and diluted net income per share:
Deemed dividends related to the Series J Preferred Stock attributable to all shareholders	-11,421,641	-24,843,481
Controlling Shareholders [Member]
Basic and diluted net income per share:
Net loss attributable to common stock	-10,154,538	-32,984,078
Undistributed net loss	-21,576,179	-57,256,985
Basic and diluted weighted average number of common shares outstanding (in Shares)	287,758,558	170,973,536
Basic and diluted net loss per common share (in Dollars per share)	($0.07)	($0.33)
Noncontrolling Shareholders [Member] | Series J Preferred Stock [Member]
Basic and diluted net income per share:
Deemed dividends related to the Series J Preferred Stock attributable to all shareholders	-3,876,619	-5,355,138
Noncontrolling Shareholders [Member]
Basic and diluted net income per share:
Net loss attributable to common stock	-3,446,552	-7,109,885
Undistributed net loss	($7,323,171)	($13,035,597)
Basic and diluted weighted average number of common shares outstanding (in Shares)	97,668,138	36,854,212
Basic and diluted net loss per common share (in Dollars per share)	($0.07)	($0.35)

Note_11_Related_Party_Transact1

Note 11 - Related Party Transactions (Details) (USD $)	1 Months Ended
	Jan. 30, 2015	Mar. 31, 2015
Series J Redeemable Convertible Preferred Stock [Member] | Holdings III [Member]
Note 11 - Related Party Transactions (Details) [Line Items]
Preferred Units, Issued	11,525
Shares Issued, Price Per Share	$1,000
Proceeds from Other Equity	$11,500,000
Pegasus Capital [Member]
Note 11 - Related Party Transactions (Details) [Line Items]
Ownership Percentage of Subsidiary Held in Parent		88.70%

Note_12_Restructuring_Expenses2

Note 12 - Restructuring Expenses (Details) (USD $)	3 Months Ended		1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	31-May-12
Note 12 - Restructuring Expenses (Details) [Line Items]
Restructuring Charges	$83,704	$205,052
Restructuring and Related Cost, Expected Cost Remaining	1,000,000
UNITED STATES | Multi-Year Initiatives [Member]
Note 12 - Restructuring Expenses (Details) [Line Items]
Restructuring And Related Cost Number Of Management Positions Replaced			10
Multi-Year Initiatives [Member]
Note 12 - Restructuring Expenses (Details) [Line Items]
Restructuring Charges	$200,000

Note_12_Restructuring_Expenses3

Note 12 - Restructuring Expenses (Details) - Restructuring Expense and Related Charges (USD $)	3 Months Ended
	Mar. 31, 2015		Mar. 31, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	$83,704		$205,052
Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	83,704	[1]	114,276	[1]
Organization Optimization Initiative [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges		[2]	$90,776	[2]
[1]	These charges relate to a significant cost reduction plan initiated during the fourth quarter of 2013 that includes moving the majority of the Company's manufacturing to its contract manufacturers in Asia, related workforce reductions in Satellite Beach, Florida and cost reductions in our foreign subsidiaries. The Company estimates it will incur $200,000 in additional expenses throughout this cost reduction plan, primarily related to additional headcount reductions. These additional costs are expected to be incurred in the first half of 2015.
[2]	In September 2011, the Company began implementing a restructuring plan designed to further increase efficiencies across the organization and lower the overall cost structure. This restructuring plan included a reduction in full time headcount in the United States, which was completed in October 2011. In 2012, the Company extended the restructuring plan to further increase efficiencies across the organization and lower its overall cost structure. The plan included a significant reduction in full time headcount in Mexico resulting from the Company's continued shift of its manufacturing and production processes to the Company's contract manufacturer in Mexico, the replacement of 10 members of management in the United States following the completion of the Series H and I Preferred Offering in May 2012 and the closing of the Company's offices in the United Kingdom and Australia. For the three months ended March 31, 2014, these expenses relate to the final liquidation of the Australian entity.

Note_12_Restructuring_Expenses4

Note 12 - Restructuring Expenses (Details) - Accrued Liability Associated with Restructuring Charges (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Restructuring Cost and Reserve [Line Items]
Accrued liability	$1,039,496	$1,451,349
Charges	83,704
Payments	-495,557
Organization Optimization Initiative [Member]
Restructuring Cost and Reserve [Line Items]
Accrued liability	620,567	959,240
Charges	83,704
Payments	-422,377
Excess Facilities [Member]
Restructuring Cost and Reserve [Line Items]
Accrued liability	244,142	311,269
Payments	-67,127
Other Exit Costs [Member]
Restructuring Cost and Reserve [Line Items]
Accrued liability	174,787	180,840
Payments	($6,053)

Note_13_Concentrations_of_Cred1

Note 13 - Concentrations of Credit Risk (Details) (Customer Concentration Risk [Member])	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Sales Revenue, Net [Member]
Note 13 - Concentrations of Credit Risk (Details) [Line Items]
Number of Customers	1	1
Concentration Risk, Percentage	80.00%	78.00%
Accounts Receivable [Member]
Note 13 - Concentrations of Credit Risk (Details) [Line Items]
Number of Customers	1		1
Concentration Risk, Percentage	81.00%		66.00%

Note_14_Commitments_and_Contin1

Note 14 - Commitments and Contingencies (Details) (Geveran Case [Member], USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015
Geveran Case [Member]
Note 14 - Commitments and Contingencies (Details) [Line Items]
Loss Contingency, Damages Sought, Value	$25